Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
University of Wisconsin School of Medicine and Public Health, Madison, WI, 53705, USA.
Oncogene. 2018 May;37(21):2817-2836. doi: 10.1038/s41388-018-0142-2. Epub 2018 Mar 7.
Tumor metastasis depends on the dynamic regulation of cell adhesion through β1-integrin. The Cub-Domain Containing Protein-1, CDCP1, is a transmembrane glycoprotein which regulates cell adhesion. Overexpression and loss of CDCP1 have been observed in the same cancer types to promote metastatic progression. Here, we demonstrate reduced CDCP1 expression in high-grade, primary prostate cancers, circulating tumor cells and tumor metastases of patients with castrate-resistant prostate cancer. CDCP1 is expressed in epithelial and not mesenchymal cells, and its cell surface and mRNA expression declines upon stimulation with TGFβ1 and epithelial-to-mesenchymal transition. Silencing of CDCP1 in DU145 and PC3 cells resulted in 3.4-fold higher proliferation of non-adherent cells and 4.4-fold greater anchorage independent growth. CDCP1-silenced tumors grew in 100% of mice, compared to 30% growth of CDCP1-expressing tumors. After CDCP1 silencing, cell adhesion and migration diminished 2.1-fold, caused by loss of inside-out activation of β1-integrin. We determined that the loss of CDCP1 reduces CDK5 kinase activity due to the phosphorylation of its regulatory subunit, CDK5R1/p35, by c-SRC on Y234. This generates a binding site for the C2 domain of PKCδ, which in turn phosphorylates CDK5 on T77. The resulting dissociation of the CDK5R1/CDK5 complex abolishes the activity of CDK5. Mutations of CDK5-T77 and CDK5R1-Y234 phosphorylation sites re-establish the CDK5/CDKR1 complex and the inside-out activity of β1-integrin. Altogether, we discovered a new mechanism of regulation of CDK5 through loss of CDCP1, which dynamically regulates β1-integrin in non-adherent cells and which may promote vascular dissemination in patients with advanced prostate cancer.
肿瘤转移依赖于通过 β1-整联蛋白对细胞黏附的动态调节。包含 Cub 结构域的蛋白 1(CDCP1)是一种调节细胞黏附的跨膜糖蛋白。在同一癌症类型中观察到 CDCP1 的过表达和缺失,以促进转移进展。在这里,我们证明了在高级别、原发性前列腺癌、去势抵抗性前列腺癌患者的循环肿瘤细胞和肿瘤转移中,CDCP1 的表达降低。CDCP1 表达于上皮细胞而非间充质细胞,并且其细胞表面和 mRNA 表达在受到 TGFβ1 和上皮-间充质转化刺激时下降。在 DU145 和 PC3 细胞中沉默 CDCP1 导致非贴壁细胞的增殖增加 3.4 倍,锚定非依赖性生长增加 4.4 倍。与表达 CDCP1 的肿瘤 30%的生长相比,沉默 CDCP1 的肿瘤在 100%的小鼠中生长。沉默 CDCP1 后,由于β1-整联蛋白的内-外激活丧失,细胞黏附和迁移减少了 2.1 倍。我们确定由于 c-SRC 对 Y234 的磷酸化,CDCP1 的丢失降低了 CDK5 激酶活性,从而导致其调节亚基 CDK5R1/p35 与 CDK5 的结合。这为 PKCδ 的 C2 结构域生成了一个结合位点,反过来又在 T77 上磷酸化 CDK5。由此产生的 CDK5R1/CDK5 复合物的解离消除了 CDK5 的活性。CDK5-T77 和 CDK5R1-Y234 磷酸化位点的突变重建了 CDK5/CDKR1 复合物和β1-整联蛋白的内-外活性。总之,我们发现了通过 CDCP1 的丢失调节 CDK5 的新机制,该机制动态调节非贴壁细胞中的β1-整联蛋白,可能促进晚期前列腺癌患者的血管扩散。